Matthew Hill
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Matthew Hill has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Cercek
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
1 shared publication - Ayyüce Begüm Bektaş
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY
1 shared publication Emmanouil Pappou
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY
1 shared publicationGarrett M. Nash
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY
1 shared publicationGeorgios Karagkounis
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY
1 shared publication- Iris Wei
Colorectal Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA
1 shared publication
Latest Publications
- 1 December 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 2 (2)
Risk of Residual Cancer After Immediate Surgery or Nonoperative Management After Malignant Colorectal Polypectomy With High-Risk Features
PURPOSE: National guidelines recommend colorectal resection when pathology from a malignant colorectal polyp reveals high-risk features (HRFs). However, some patients opt to avoid surgery because of concerns about associated morbidity and potential impacts on quality of life, despite the risk of residual disease. METHODS: In this single-center cohort study of patients treated between 2015 and 2022, we retrospectively compared rates of residual disease between patients who underwent immediate surgery and patients managed nonoperatively after removal of a malignant polyp with HRFs. RESULTS: Of 336 patients who underwent a polypectomy in the colon (n = 226) or rectum (n = 110) and had at least one HRF, 208 (62%) underwent immediate surgery and 128 (38%) were managed nonoperatively. Residual disease was identified in 63 patients (19%), either at the time of immediate surgery or during surveillance in the nonoperative group. In the immediate surgery group, 51 (25%) patients had residual disease, including 19 (9%) with residual disease in the bowel wall and 39 (19%) in locoregional lymph nodes (LNs). In the nonoperative cohort group, 12 (9%) developed recurrence after polypectomy during surveillance, including 7 (6%) in the bowel wall and 5 (4%) in locoregional LNs. In the nonoperative group, all recurrences after polypectomy were successfully treated with salvage surgery (n = 6) or chemoradiotherapy (n = 6). Distant metastases occurred in 2% of patients. CONCLUSION: The risk of residual disease after removal of a malignant polyp with HRFs approaches 20%. Patients who are concerned about the potential morbidity of surgery and its impact on postoperative quality of life should be counseled about this risk, as well as the availability of effective salvage treatments after nonoperative surveillance.
- 1 December 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 2 (2)
Risk of Residual Cancer After Immediate Surgery or Nonoperative Management After Malignant Colorectal Polypectomy With High-Risk Features
PURPOSE: National guidelines recommend colorectal resection when pathology from a malignant colorectal polyp reveals high-risk features (HRFs). However, some patients opt to avoid surgery because of concerns about associated morbidity and potential impacts on quality of life, despite the risk of residual disease. METHODS: In this single-center cohort study of patients treated between 2015 and 2022, we retrospectively compared rates of residual disease between patients who underwent immediate surgery and patients managed nonoperatively after removal of a malignant polyp with HRFs. RESULTS: Of 336 patients who underwent a polypectomy in the colon (n = 226) or rectum (n = 110) and had at least one HRF, 208 (62%) underwent immediate surgery and 128 (38%) were managed nonoperatively. Residual disease was identified in 63 patients (19%), either at the time of immediate surgery or during surveillance in the nonoperative group. In the immediate surgery group, 51 (25%) patients had residual disease, including 19 (9%) with residual disease in the bowel wall and 39 (19%) in locoregional lymph nodes (LNs). In the nonoperative cohort group, 12 (9%) developed recurrence after polypectomy during surveillance, including 7 (6%) in the bowel wall and 5 (4%) in locoregional LNs. In the nonoperative group, all recurrences after polypectomy were successfully treated with salvage surgery (n = 6) or chemoradiotherapy (n = 6). Distant metastases occurred in 2% of patients. CONCLUSION: The risk of residual disease after removal of a malignant polyp with HRFs approaches 20%. Patients who are concerned about the potential morbidity of surgery and its impact on postoperative quality of life should be counseled about this risk, as well as the availability of effective salvage treatments after nonoperative surveillance.